Skip to content

Distal Perfusion Timing, Early or Conservative, to Prevent Limb Ischemia During Peripheral VA-ECMO

Comparison Of Conservative Versus Early Distal Perfusion Strategy to Prevent Acute Limb Ischemia in Peripheral Venoarterial Extracorporeal Membrane Oxygenation Patients

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05698628
Acronym
DECIDE-ECMO
Enrollment
400
Registered
2023-01-26
Start date
2023-04-28
Completion date
2027-02-28
Last updated
2023-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Extracorporeal Membrane Oxygenation Complication

Keywords

Extracorporeal Membrane Oxygenation, Limb ischemia, Cardiogenic shock

Brief summary

Peripheral VA-ECMO is widely used in refractory cardiogenic shock patients as a salvage therapy. In most cases, the femoral artery and vein are used for the vascular approach. Large cannulas are usually used for proper oxygenation, which may cause peripheral limb ischemia. Distal perfusion catheterization (DPC) at the ipsilateral arterial cannula site is recommended to prevent distal limb ischemia. However, there is no consensus on the proper timing of DPC and additional invasive procedures may cause complications during VA-ECMO support. In this analysis, the investigators compare the clinical outcomes of distal limb ischemia complications between the conventional DPC group (DPC at the time of limb ischemia sign) and the preemptive DPC group (DPC at the time of VA-ECMO application).

Interventions

PROCEDUREDistal perfusion catheterization

Distal perfusion catheterization will be done within 1 hour after the VA-ECMO application in the preemptive DPC group. The conventional DPC group will undergo distal perfusion catheterization at the time of limb ischemia sign.

Sponsors

Min-Seok Kim
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥19 years old * Refractory cardiogenic shock with peripheral VA-ECMO * Informed consent

Exclusion criteria

* Unwilling or unable to obtain informed consent from the participant or substitute decision-maker * Patients who are currently pregnant, postpartum period within 30 days or are breast-feeding * VA-ECMO application for causes other than cardiogenic shock * Severe coagulopathy * Irreversible limb ischemia requiring interventional procedures or surgery at the time of VA-ECMO (previously diagnosed ASO(atherosclerosis obliterans) patients)

Design outcomes

Primary

MeasureTime frameDescription
Limb ischemiaFrom date of randomization until the date of discharge or assessed up to 90 daysLimb ischemia requiring surgical/percutaneous procedure or resulting necrosis or neurologic sequelae in the distal limb during hospitalization

Secondary

MeasureTime frameDescription
All-cause mortalityFrom date of randomization until the date of death from any cause, assessed up to 12 monthsAll-cause of death
Successful ECMO weaningFrom date of randomization until the date of discharge or assessed up to 90 daysHaving ECMO removed and not requiring further mechanical support because of recurring cardiogenic shock over the following 30 days
ECMO related complicationsFrom date of randomization until the date of ECMO removal, assesed up to 90 daysBleeding, systemic thromboembolism, etc.

Countries

South Korea

Contacts

Primary ContactMin-Seok Kim, PhD
msk@amc.seoul.kr82-2-3010-3948
Backup ContactAh-Ram Kim, MD
ahram3256@amc.seoul.kr82-2-3010-0111

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026